71
Participants
Start Date
April 17, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Brentuximab vedotin
Brentuximab vedotin will be administered at 1.2 mg/kg IV on days 1 and 15 of each 28-day cycle
Doxorubicin
Doxorubicin 25 mg/m\^2 IV
Vinblastine
Vinblastine 6 mg/m\^2 IV
Dacarbazine
Dacarbazine 375 mg/m\^2 IV on days 1 and 15 of each 28-day cycle
Pembrolizumab
Pembrolizumab will be administered at 200 mg IV (flat) on day 1
Gemcitabine
Gemcitabine 1000 mg/m\^2 IV (days 1 an
Vinorelbine
Vinblastine 6 mg/m\^2 IV
FDG-PET/CT scan
After 2 cycles of therapy, patients will undergo FDG-PET/CT scan
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale
RECRUITING
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
NOT_YET_RECRUITING
University of Miami, Miami
RECRUITING
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Seagen Inc.
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER